Invivyd (IVVD) News Today $0.76 -0.04 (-5.03%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 15.8% in OctoberInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 8,270,000 shares, an increase of 15.8% from the October 15th total of 7,140,000 shares. Approximately 11.4% of the company's stock are sold short. Based on an average daily trading volume, of 463,300 shares, the days-to-cover ratio is currently 17.9 days.November 16 at 4:36 PM | marketbeat.comInvivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...November 16 at 1:40 AM | nz.finance.yahoo.comInvivyd’s Q3 2024: Revenue Growth and Strategic DevelopmentsNovember 16 at 1:40 AM | markets.businessinsider.comInvivyd, Inc. (NASDAQ:IVVD) Q3 2024 Earnings Call TranscriptNovember 16 at 1:40 AM | msn.comEarnings Outlook For InvivydNovember 14 at 9:11 PM | benzinga.comInvivyd reports Q3 EPS (51c) vs (36c) last yearNovember 14 at 9:11 PM | markets.businessinsider.comInvivyd announces NEJM published letter to editor on PEMGARDANovember 14 at 9:11 PM | markets.businessinsider.comInvivyd, Inc. (IVVD) Q3 2024 Earnings Call TranscriptNovember 14 at 3:00 PM | seekingalpha.comInvivyd Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14 at 7:05 AM | globenewswire.comInvivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the EditorNovember 14 at 7:01 AM | globenewswire.comInvivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, RespectivelyNovember 12, 2024 | globenewswire.comInvivyd (IVVD) Scheduled to Post Quarterly Earnings on ThursdayInvivyd (NASDAQ:IVVD) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comInvivyd to Participate in the Guggenheim Securities Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.comInvivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024November 6, 2024 | globenewswire.comInvivyd (NASDAQ:IVVD) Raised to Strong-Buy at EF Hutton Acquisition Co. IEF Hutton Acquisition Co. I raised Invivyd to a "strong-buy" rating in a research report on Wednesday.November 1, 2024 | marketbeat.comEF Hutton Initiates Coverage of Invivyd (IVVD) with Buy RecommendationOctober 31, 2024 | msn.comInvivyd’s PEMGARDA Shows Promising Phase 3 Results and Strong Market Potential Amidst FDA ClarificationOctober 30, 2024 | markets.businessinsider.comInvivyd reports preliminary Q3 PEMGARDA product revenue $9.3MOctober 29, 2024 | markets.businessinsider.comInvivyd announces 12-month exploratory data from CANOPY Phase 3 trialOctober 29, 2024 | markets.businessinsider.comInvivyd (NASDAQ:IVVD) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Invivyd in a report on Tuesday.October 29, 2024 | marketbeat.comInvivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term ProfitabilityOctober 29, 2024 | globenewswire.comInvivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent ParticipantsOctober 29, 2024 | globenewswire.comInvivyd, Inc. (NASDAQ:IVVD) Short Interest Down 8.0% in SeptemberInvivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 6,810,000 shares, a decrease of 8.0% from the September 15th total of 7,400,000 shares. Approximately 9.4% of the shares of the stock are sold short. Based on an average trading volume of 438,400 shares, the days-to-cover ratio is presently 15.5 days.October 16, 2024 | marketbeat.comInvivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024October 16, 2024 | globenewswire.comInvivyd (NASDAQ:IVVD) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comInvivyd Announces U.S. FDA Has Updated the PEMGARDA(TM) EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity DataOctober 1, 2024 | stockhouse.comInvivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity DataOctober 1, 2024 | globenewswire.comDuquesne Family Office LLC Takes $629,000 Position in Invivyd, Inc. (NASDAQ:IVVD)Duquesne Family Office LLC acquired a new position in Invivyd, Inc. (NASDAQ:IVVD - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 571,425 shares of the company's stock, valued at approximately $629,000. Duquesne FamilSeptember 26, 2024 | marketbeat.comBuy Rating Affirmed for Invivyd on Pemgarda’s Efficacy and Promising Revenue ProjectionsSeptember 25, 2024 | markets.businessinsider.comInvivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)September 23, 2024 | globenewswire.comInvivyd, Inc. (NASDAQ:IVVD) Stock Holdings Lifted by Acadian Asset Management LLCAcadian Asset Management LLC increased its holdings in Invivyd, Inc. (NASDAQ:IVVD - Free Report) by 232.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 678,706 shares of the company's stock after buying an additional 474,301 shares during the period. AcadSeptember 18, 2024 | marketbeat.comInvivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19September 12, 2024 | globenewswire.comBuy Rating Affirmed for Invivyd: Strong Product Performance and Strategic Market InitiativesSeptember 9, 2024 | markets.businessinsider.comInvivyd to Participate in Upcoming Investor ConferencesSeptember 5, 2024 | globenewswire.comInvivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™September 4, 2024 | globenewswire.comBuy Rating Affirmed for Invivyd Amid Strong Potential of PEMGARDA Antibody for COVID-19 VariantsSeptember 3, 2024 | markets.businessinsider.comInvivyd's (IVVD) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Invivyd in a research report on Tuesday.September 3, 2024 | marketbeat.comInvivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of InterestSeptember 3, 2024 | globenewswire.comBuy Rating on Invivyd Backed by Strong Phase 3 Data and Market CatalystsAugust 29, 2024 | markets.businessinsider.comInvivyd Announces Positive 180-day Clinical Efficacy Data From CANOPY Phase 3 Trial Of PemivibartAugust 27, 2024 | markets.businessinsider.comInvivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical TrialAugust 27, 2024 | globenewswire.comInvivyd, Inc. (NASDAQ:IVVD) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comInvivyd, Inc. (IVVD) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comInvivyd Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 14, 2024 | globenewswire.comInvivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business HighlightsAugust 12, 2024 | globenewswire.comInvivyd (NASDAQ:IVVD) Shares Up 7.2%Invivyd (NASDAQ:IVVD) Stock Price Up 7.2%July 25, 2024 | marketbeat.comInvivyd Announces its Addition to the Russell 2000® and Russell 3000® IndexesJuly 1, 2024 | globenewswire.comInvivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 VariantsJune 14, 2024 | globenewswire.comInvivyd to Participate at the Jefferies Global Healthcare ConferenceJune 3, 2024 | globenewswire.comInvivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire Sells 112,381 SharesJune 1, 2024 | insidertrades.com Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics… Get Your Free Gold Guide IVVD Media Mentions By Week IVVD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVVD News Sentiment▼0.290.55▲Average Medical News Sentiment IVVD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVVD Articles This Week▼132▲IVVD Articles Average Week Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MCRB News Today BLUE News Today KRON News Today ESPR News Today GHRS News Today XERS News Today DNA News Today KALV News Today ORGO News Today AQST News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVVD) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IVVD Stock Alerts